Table 2.

DPWG (2016) Recommendations for Carvedilol and CYP2D6

PhenotypeRecommendations
CYP2D6 poor metabolizersNo action is required for this gene-drug interaction.
The plasma concentration of carvedilol can be elevated. This does not, however, result in an increase in side effects.
CYP2D6 intermediate metabolizersNo action is required for this gene-drug interaction.
The plasma concentration of carvedilol can be elevated. This does not, however, result in an increase in side effects.
CYP2D6 ultrarapid metabolizersNo action is required for this gene-drug interaction.
The plasma concentration of carvedilol can be reduced. This does not, however, result in a decrease in the effectiveness.

Please see Therapeutic Recommendations based on Genotype for more information from DPWG. This table is adapted from (2).

From: Carvedilol Therapy and CYP2D6 Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.